{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Acute disabling relapse with brainstem involvement Improves speed of recovery in optic neuritis/demyelination Low risk after screening for infection\n\n*   **Treatment:** Proton pump inhibitor while on high-dose steroids\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Gastroprotection during corticosteroid course\n\n*   **Treatment:** Eye protection for left facial palsy (lubricating drops and eyelid taping at night)\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Incomplete eyelid closure risks exposure keratopathy\n\n*   **Treatment:** Venous thromboembolism prophylaxis and early physiotherapy\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Reduced mobility from hemiparesis increases VTE risk Prevents deconditioning and aids recovery\n\n*   **Treatment:** Plasma exchange\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserve for poor response to steroids within 5\u20137 days Indicated early if NMOSD strongly suspected or severe deficits persist\n\n*   **Treatment:** Initiate disease-modifying therapy for MS (agent per risk profile)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start after diagnostic confirmation and serology (AQP4/MOG) to choose appropriate therapy Need MRI/CSF to stratify disease activity and safety\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Acute disabling relapse with brainstem involvement\", \"Improves speed of recovery in optic neuritis/demyelination\", \"Low risk after screening for infection\"]}, {\"treatment\": \"Proton pump inhibitor while on high-dose steroids\", \"timing\": \"Start Now\", \"reasons\": [\"Gastroprotection during corticosteroid course\"]}, {\"treatment\": \"Eye protection for left facial palsy (lubricating drops and eyelid taping at night)\", \"timing\": \"Start Now\", \"reasons\": [\"Incomplete eyelid closure risks exposure keratopathy\"]}, {\"treatment\": \"Venous thromboembolism prophylaxis and early physiotherapy\", \"timing\": \"Start Now\", \"reasons\": [\"Reduced mobility from hemiparesis increases VTE risk\", \"Prevents deconditioning and aids recovery\"]}, {\"treatment\": \"Plasma exchange\", \"timing\": \"Delay\", \"reasons\": [\"Reserve for poor response to steroids within 5\\u20137 days\", \"Indicated early if NMOSD strongly suspected or severe deficits persist\"]}, {\"treatment\": \"Initiate disease-modifying therapy for MS (agent per risk profile)\", \"timing\": \"Delay\", \"reasons\": [\"Start after diagnostic confirmation and serology (AQP4/MOG) to choose appropriate therapy\", \"Need MRI/CSF to stratify disease activity and safety\"]}]"
}